A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Wednesday, 17 July 2013
AstraZeneca to Collaborate with Tufts University AstraZeneca and Tufts University’s School of Medicine and Sackler School of Graduate Biomedical Sciences are collaborating to establish a team of postdoctoral researchers that will work to advance understanding of diseases and disorders of the brain, including Alzheimer’s disease, Parkinson’s disease, neurodevelopmental and autism spectrum disorders. As part of a three-year agreement, the new team will conduct cutting-edge laboratory research into biological targets of interest in the field of neuroscience.
Wednesday, 26 June 2013
Roche and AstraZeneca launch medicinal chemistry data-sharing consortium to further accelerate drug discovery MedChemica to intermediate this unique collaboration
Tuesday, 25 June 2013
AstraZeneca and Karolinska Institutet sign agreement on integrated centre for cardiovascular and metabolic diseases AstraZeneca today announces the finalisation of a definitive agreement with Karolinska Institutet, Stockholm, Sweden regarding the establishment of a unique joint centre for research on cardiovascular and metabolic diseases.
Wednesday, 19 June 2013
Nobel Laureate Peter Agre speaks at the inaugural Nobel Prize Inspiration Initiative event in Russia On June 24-26 in Moscow and St.Petersburg, Professor Peter Agre, awarded the 2003 Nobel Prize in Chemistry, will participate in the Nobel Prize Inspiration Initiative, a global program that brings Nobel Laureates to universities and research centers to inspire and engage young scientists, the scientific community and the public.
Friday, 14 June 2013
Cancer Research Technology, University of Manchester and AstraZeneca work together to seek new cancer drugs Cancer Research Technology, the commercial arm of Cancer Research UK, the University of Manchester and AstraZeneca announced two agreements to seek new cancer drugs.
Thursday, 30 May 2013
NEOMED and AstraZeneca broaden strategic alliance in discovery research, share compound libraries Montreal, May 29 2013 – NEOMED and AstraZeneca announced today the expansion of their strategic partnership, further enabling NEOMED’s mission of delivering novel therapeutic solutions for unmet medical needs. AstraZeneca will provide NEOMED access to up to 250,000 high-quality compounds from its small molecule compound library to be used to identify candidate compounds for selected targets. The goal is to identify compounds that could potentially become new medicines for a broad range of diseases.
Tuesday, 28 May 2013
AstraZeneca awarded grant by the Michael J. Fox Foundation to investigate a nicotine receptor agonist as treatment of Dyskinesia in Parkinson’s Disease AstraZeneca today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded AstraZeneca a grant to support research on levodopa-induced dyskinesias (LID), a complication of therapies commonly used to reduce Parkinson’s disease symptoms.
Tuesday, 21 May 2013
AstraZeneca and Massachusetts General Hospital To Identify New Combination Therapies For Cancer AstraZeneca today announced it has entered into a collaboration with Massachusetts General Hospital (MGH) to identify patients who might benefit from unique combinations of investigational and marketed cancer therapies.
Wednesday, 24 April 2013
Alchemia Announces Multi-Target Drug Discovery Collaboration with AstraZeneca on VAST Discovery Platform Brisbane,  Australia 22 April 2013 –  Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca PLC.
Monday, 22 April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca Cambridge, UK, 22 April 2013: Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.